Assays to detect the cancer-associated antigen in serum (for example, the CA15.3 assay) are widely used for monitoring disease progression and response to therapy in some late stage breast cancer patients, but this assay does not detect elevated levels of MUC1 in serum from patients with early stage disease [5]. This evidence concerns the gene MUC1 and breast carcinoma.